AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$LUNG

Radhakrishnan Srikanth sold $22K of LUNG

Radhakrishnan Srikanth (Chief Science &Techn. Officer) sold 14,497 shares of Pulmonx Corp (LUNG) at $1.54 across 4 trades on 2026-06-01.

Original reporting
SEC EDGAR · Radhakrishnan Srikanth
Published Jun 3, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LUNG
Bearish
medium confidence
Mentioned
$LUNG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGBearishLow
01

Why it matters

A modest insider sell may slightly depress the stock but is unlikely to move the market.

02

Market read

The filing provides a new data point for investors monitoring insider activity at Pulmonx.

03

What to watch

The officer retains a large stake (over 330k shares) indicating continued confidence.

Relevance 3/10Novelty 3/10Timing: post‑market filing

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$LUNGBearishMedium confidence
Context

Chief Science & Techn. Officer sold 14,497 shares for $22,325, reducing his stake.

Expected impact

likely modest pressure as market prices in the insider sell

Evidence & confidence

Small sale size relative to holdings, but insider is a senior officer; investors may view it as a mild negative signal.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

No notable regional effect.

Global

Limited to investors tracking Pulmonx.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Officer
    Radhakrishnan Srikanth

    Chief Science & Techn. Officer of Pulmonx Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LUNG insider trading history →

Related articles

OCT 27
$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.

finance.yahoo.com3 min
OCT 27
$LUNGMed

Pulmonx Reports Third Quarter 2026 Financial Results

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Third Quarter 2026 Financial Results Redwood City, CA - October 27, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the thi

SEC EDGAR 8-K2 min
JUL 31
$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

rttnews.com6 min